Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411975 | 0.93 | SOS1 (0.48) | SOS1GPR27NOTUMLMNATSHR | |
| SCHEMBL14955873 | 0.86 | SOS1 (0.44) | SOS1NOTUMLMNATSHRNPSR1 | |
| SCHEMBL1044961 | 0.85 | SOS1 (0.46) | SOS1GPR27NOTUMLMNATSHR | |
| SCHEMBL19993672 | 0.85 | MAPT (0.42) | SOS1NOTUMLMNATSHRMAPT | |
| SCHEMBL5154161 | 0.85 | SOS1 (0.45) | SOS1NOTUMLMNATSHRMAPT | |
| SCHEMBL1418414 | 0.83 | PDGFRB (0.42) | NOTUMLMNATSHRMAPTCA12 | |
| SCHEMBL18420521 | 0.83 | NOTUM (0.45) | SOS1GPR27NOTUMLMNATSHR | |
| SCHEMBL14186809 | 0.83 | MAPT (0.41) | LMNATSHRMAPTCA12CA1 | |
| SCHEMBL31385726 | 0.83 | NOTUM (0.45) | SOS1GPR27NOTUMLMNATSHR | |
| SCHEMBL20772841 | 0.82 | CCR6 (0.46) | SOS1NOTUMLMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-12172995-B2 | Substituted indole and indazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| CN-119039290-A | P2X3 modulators | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| CN-117088884-A | Imidazopyridazine derivatives as GABAA receptor modulators, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230312557-A1 | P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312557-A1 | P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| EP-2683693-A1 | RORGAMMAT INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | SOS1 2825/4885GPR27 1811/4885NOTUM 4118/4885 |
| US-20230312557-A1 | P2X3 MODULATORS | P2RX3, P2RX2, P2RX6 | SOS1 3957/4885GPR27 457/4885NOTUM 4763/4885 |
| US-12172995-B2 | Substituted indole and indazole compounds | TLR1, TLR7, IDO1 | SOS1 1253/4885GPR27 107/4885NOTUM 4497/4885 |
| US-20140038942-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | SOS1 718/4885GPR27 61/4885NOTUM 3780/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | SOS1 171/4885GPR27 675/4885NOTUM 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.